Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.

Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH.

J Immunother Cancer. 2019 Oct 22;7(1):272. doi: 10.1186/s40425-019-0730-x.

3.

Are Conditioned Open Placebos Feasible as an Adjunctive Treatment to Opioids? Results from a Single-Group Dose-Extender Pilot Study with Acute Pain Patients.

Bernstein MH, Magill M, Weiss AP, Kaptchuk TJ, Blease C, Kirsch I, Rich JD, Becker SJ, Mach S, Beaudoin FL.

Psychother Psychosom. 2019 Sep 27:1-3. doi: 10.1159/000503038. [Epub ahead of print] No abstract available.

4.

Should antidepressants be used for major depressive disorder?

Jakobsen JC, Gluud C, Kirsch I.

BMJ Evid Based Med. 2019 Sep 25. pii: bmjebm-2019-111238. doi: 10.1136/bmjebm-2019-111238. [Epub ahead of print] Review.

5.

Treatments for depression: Side-effects, adverse events and health risks.

Kirsch I, Ness AR, Appleton KM.

J Affect Disord. 2019 Dec 1;259:38-39. doi: 10.1016/j.jad.2019.08.018. Epub 2019 Aug 13. No abstract available.

PMID:
31437699
6.

Placebo Effect in the Treatment of Depression and Anxiety.

Kirsch I.

Front Psychiatry. 2019 Jun 13;10:407. doi: 10.3389/fpsyt.2019.00407. eCollection 2019. Review.

7.

A test of positive suggestions about side effects as a way of enhancing the analgesic response to NSAIDs.

Fernandez A, Kirsch I, Noël L, Rodondi PY, Kaptchuk TJ, Suter MR, Décosterd I, Berna C.

PLoS One. 2019 Jan 3;14(1):e0209851. doi: 10.1371/journal.pone.0209851. eCollection 2019.

8.

High-throughput sequencing of the T-cell receptor β chain gene distinguishes 2 subgroups of cutaneous T-cell lymphoma.

Wang J, Rea B, Haun P, Emerson R, Kirsch I, Bagg A.

J Am Acad Dermatol. 2019 Apr;80(4):1148-1150.e1. doi: 10.1016/j.jaad.2018.10.027. Epub 2018 Oct 23. No abstract available.

PMID:
30365996
9.

Network meta-analysis of antidepressants.

Kirsch I, Jakobsen JC.

Lancet. 2018 Sep 22;392(10152):1010. doi: 10.1016/S0140-6736(18)31799-9. Epub 2018 Sep 20. No abstract available.

PMID:
30264698
10.

Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus.

Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, Büchel C, Carvalho C, Colagiuri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klinger R, Kelley JM.

Psychother Psychosom. 2018;87(4):204-210. doi: 10.1159/000490354. Epub 2018 Jun 12.

11.

Enhancing treatment of osteoarthritis knee pain by boosting expectancy: A functional neuroimaging study.

Kong J, Wang Z, Leiser J, Minicucci D, Edwards R, Kirsch I, Wasan AD, Lang C, Gerber J, Yu S, Napadow V, Kaptchuk TJ, Gollub RL.

Neuroimage Clin. 2018 Feb 28;18:325-334. doi: 10.1016/j.nicl.2018.01.021. eCollection 2018.

12.

High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.

de Masson A, O'Malley JT, Elco CP, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS.

Sci Transl Med. 2018 May 9;10(440). pii: eaar5894. doi: 10.1126/scitranslmed.aar5894.

13.

Response Expectancy and the Placebo Effect.

Kirsch I.

Int Rev Neurobiol. 2018;138:81-93. doi: 10.1016/bs.irn.2018.01.003. Epub 2018 Feb 28. Review.

PMID:
29681336
14.

Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma.

Rea B, Haun P, Emerson R, Vignali M, Farooqi M, Samimi S, Elenitsas R, Kirsch I, Bagg A.

J Clin Pathol. 2018 Sep;71(9):814-820. doi: 10.1136/jclinpath-2018-205004. Epub 2018 Apr 10.

PMID:
29636372
15.

A Functional Neuroimaging Study of Expectancy Effects on Pain Response in Patients With Knee Osteoarthritis.

Gollub RL, Kirsch I, Maleki N, Wasan AD, Edwards RR, Tu Y, Kaptchuk TJ, Kong J.

J Pain. 2018 May;19(5):515-527. doi: 10.1016/j.jpain.2017.12.260. Epub 2018 Jan 8.

16.

Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.

Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, Borowitz MJ, Devidas M, Maloney KW, Larsen E, Winick N, Raetz E, Carroll WL, Hunger SP, Loh ML, Robins H, Kirsch I.

Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28.

17.

The clinical significance of drug-placebo differences.

Kirsch I.

Epidemiol Psychiatr Sci. 2018 Jun;27(3):240-241. doi: 10.1017/S2045796017000725. Epub 2017 Nov 23. No abstract available.

PMID:
29166967
18.

Response Expectancy and the Response to Antidepressant Medication.

Kirsch I.

EBioMedicine. 2017 Nov;25:13. doi: 10.1016/j.ebiom.2017.09.038. Epub 2017 Oct 2. No abstract available.

19.

Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones.

Matos TR, O'Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, Kupper TS, Krueger JG, Clark RA.

J Clin Invest. 2017 Nov 1;127(11):4031-4041. doi: 10.1172/JCI93396. Epub 2017 Sep 25.

20.

Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.

Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, Kessler RC, Kossowsky J.

JAMA Psychiatry. 2017 Oct 1;74(10):1011-1020. doi: 10.1001/jamapsychiatry.2017.2432.

21.

Is the rationale more important than deception? A randomized controlled trial of open-label placebo analgesia.

Locher C, Frey Nascimento A, Kirsch I, Kossowsky J, Meyer A, Gaab J.

Pain. 2017 Dec;158(12):2320-2328. doi: 10.1097/j.pain.0000000000001012.

PMID:
28708766
22.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

23.

Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial.

Ballou S, Kaptchuk TJ, Hirsch W, Nee J, Iturrino J, Hall KT, Kelley JM, Cheng V, Kirsch I, Jacobson E, Conboy L, Lembo A, Davis RB.

Trials. 2017 May 25;18(1):234. doi: 10.1186/s13063-017-1964-x.

24.

Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis.

Sugarman MA, Kirsch I, Huppert JD.

J Affect Disord. 2017 Aug 15;218:217-226. doi: 10.1016/j.jad.2017.04.068. Epub 2017 Apr 29. Review.

PMID:
28477500
25.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

26.

Certainty of genuine treatment increases drug responses among intellectually disabled patients.

Jensen KB, Kirsch I, Pontén M, Rosén A, Yang K, Gollub RL, des Portes V, Kaptchuk TJ, Curie A.

Neurology. 2017 May 16;88(20):1912-1918. doi: 10.1212/WNL.0000000000003934. Epub 2017 Apr 19.

27.

Reply.

Carvalho C, Kirsch I, Kaptchuk TJ.

Pain. 2017 Mar;158(3):536-537. doi: 10.1097/j.pain.0000000000000795. No abstract available.

PMID:
28187105
28.

Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial.

Berna C, Kirsch I, Zion SR, Lee YC, Jensen KB, Sadler P, Kaptchuk TJ, Edwards RR.

Pain. 2017 Jun;158(6):1014-1020. doi: 10.1097/j.pain.0000000000000870.

29.

Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Sala Torra O, Othus M, Williamson DW, Wood B, Kirsch I, Robins H, Beppu L, O'Donnell MR, Forman SJ, Appelbaum FR, Radich JP.

Biol Blood Marrow Transplant. 2017 Apr;23(4):691-696. doi: 10.1016/j.bbmt.2016.12.639. Epub 2017 Jan 3.

30.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:76. eCollection 2016. Review.

31.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. Review.

32.

Parental Attitudes About Placebo Use in Children.

Faria V, Kossowsky J, Petkov MP, Kaptchuk TJ, Kirsch I, Lebel A, Borsook D.

J Pediatr. 2017 Feb;181:272-278.e10. doi: 10.1016/j.jpeds.2016.10.018. Epub 2016 Nov 15.

PMID:
27863847
33.

Open-label placebo treatment in chronic low back pain: a randomized controlled trial.

Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I.

Pain. 2016 Dec;157(12):2766-2772. Erratum in: Pain. 2017 Feb;158(2):365.

34.

Effects of subtle cognitive manipulations on placebo analgesia - An implicit priming study.

Rosén A, Yi J, Kirsch I, Kaptchuk TJ, Ingvar M, Jensen KB.

Eur J Pain. 2017 Apr;21(4):594-604. doi: 10.1002/ejp.961. Epub 2016 Oct 17.

35.

Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials.

Rutherford BR, Wall MM, Brown PJ, Choo TH, Wager TD, Peterson BS, Chung S, Kirsch I, Roose SP.

Am J Psychiatry. 2017 Feb 1;174(2):135-142. doi: 10.1176/appi.ajp.2016.16020225. Epub 2016 Sep 9.

36.

Eosinophil-Rich Acute Febrile Neutrophilic Dermatosis in a Patient With Enteropathy-Associated T-cell Lymphoma, Type 1.

Soon CW, Kirsch IR, Connolly AJ, Kwong BY, Kim J.

Am J Dermatopathol. 2016 Sep;38(9):704-8. doi: 10.1097/DAD.0000000000000549.

PMID:
27097333
37.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

38.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

39.

Not seeing or feeling is still believing: conscious and non-conscious pain modulation after direct and observational learning.

Egorova N, Park J, Orr SP, Kirsch I, Gollub RL, Kong J.

Sci Rep. 2015 Nov 18;5:16809. doi: 10.1038/srep16809.

40.

TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL.

Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, Teague JE, Gehad A, Lowry EL, LeBoeuf NR, Krueger JG, Robins HS, Kupper TS, Clark RA.

Sci Transl Med. 2015 Oct 7;7(308):308ra158. doi: 10.1126/scitranslmed.aaa9122.

41.

Clinical trial methodology and drug-placebo differences.

Kirsch I.

World Psychiatry. 2015 Oct;14(3):301-2. doi: 10.1002/wps.20242. No abstract available.

42.

T-cell receptor profiling in cancer.

Kirsch I, Vignali M, Robins H.

Mol Oncol. 2015 Dec;9(10):2063-70. doi: 10.1016/j.molonc.2015.09.003. Epub 2015 Sep 15. Review.

43.

High-throughput pairing of T cell receptor α and β sequences.

Howie B, Sherwood AM, Berkebile AD, Berka J, Emerson RO, Williamson DW, Kirsch I, Vignali M, Rieder MJ, Carlson CS, Robins HS.

Sci Transl Med. 2015 Aug 19;7(301):301ra131. doi: 10.1126/scitranslmed.aac5624. Erratum in: Sci Transl Med. 2015 Oct 14;7(309):309er7.

PMID:
26290413
44.

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA.

Blood. 2015 Sep 17;126(12):1452-61. doi: 10.1182/blood-2015-02-630335. Epub 2015 Jul 30. Erratum in: Blood. 2015 Dec 17;126(25):2765. Gelfand, Joel C [corrected to Gelfand, Joel M].

45.

Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.

Curie A, Yang K, Kirsch I, Gollub RL, des Portes V, Kaptchuk TJ, Jensen KB.

PLoS One. 2015 Jul 30;10(7):e0133316. doi: 10.1371/journal.pone.0133316. eCollection 2015.

46.

Immune monitoring technology primer: immunosequencing.

Kirsch I.

J Immunother Cancer. 2015 Jun 25;3:29. doi: 10.1186/s40425-015-0076-y. eCollection 2015.

47.

Classical conditioning of analgesic and hyperalgesic pain responses without conscious awareness.

Jensen K, Kirsch I, Odmalm S, Kaptchuk TJ, Ingvar M.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7863-7. doi: 10.1073/pnas.1504567112. Epub 2015 May 15.

48.

Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences.

Moncrieff J, Kirsch I.

Contemp Clin Trials. 2015 Jul;43:60-2. doi: 10.1016/j.cct.2015.05.005. Epub 2015 May 12.

49.

Grounding Hypnosis in Science: The "New" APA Division 30 Definition of Hypnosis as a Step Backward.

Lynn SJ, Green JP, Kirsch I, Capafons A, Lilienfeld SO, Laurence JR, Montgomery GH.

Am J Clin Hypn. 2015 Apr;57(4):390-401. doi: 10.1080/00029157.2015.1011472. No abstract available.

PMID:
25928778
50.

Hypnosis, suggestion, and suggestibility: an integrative model.

Lynn SJ, Laurence JR, Kirsch I.

Am J Clin Hypn. 2015 Jan;57(3):314-29. doi: 10.1080/00029157.2014.976783.

PMID:
25928681

Supplemental Content

Loading ...
Support Center